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Genetic mutationGenetic mutations in H-Ras cause Costello syndrome (CS), a complex developmental disorder associated
with cortical abnormalities and profound mental retardation. Here, we have asked whether there are
perturbations in precursor cell proliferation, differentiation, or survival as a consequence of expressing CS
H-Ras alleles that could explain the cognitive deﬁcits seen in this disorder. Two different H-Ras alleles
encoding mutations present in CS patients, H-RasG12V and H-RasG12S were expressed in cortical
progenitors in culture and in vivo by in utero electroporation and their effects on cortical precursor cell fate
examined. Expression of both mutants in cultured precursors inhibited neurogenesis and promoted
proliferation and astrogenesis. In vivo, expression of either form of CS H-Ras promoted cell proliferation and
inhibited neurogenesis. Moreover, these H-Ras mutants promoted premature gliogenesis, causing formation
of astrocytes at a time when normal gliogenesis has not yet begun, ultimately leading to an increase in the
number of astrocytes postnatally. Thus, aberrant H-Ras activation enhances neural precursor cell
proliferation, and perturbs the normal genesis of neurons and glial cells, effects that likely contribute to
the cortical abnormalities and cognitive dysfunction seen in CS.Introduction
During mammalian development, the cerebral cortex is generated
through a heterogeneous pool of precursor cells that can produce
neurons and glial cells. Emerging evidence suggests that growth
factors determine the precise timing and extent of the genesis of these
two cell types (Miller and Gauthier, 2007). In vivo, cortical neuro-
genesis starts early in development at embryonic day 12 (E12) and
ends at around E18, at which point astrogenesis starts and continues
through the ﬁrst weeks of life. These sequential waves of differen-
tiation are regulated by both intrinsic mechanisms and growth factors
in the neural environment. Many of these growth factors converge
onto the Ras signaling pathway, which has been shown to play a
central role in regulating neural precursor cell proliferation, survival,
and cell fate decisions (Samuels et al., 2009). With speciﬁc regard to
the developing cortex, aberrant H-Ras activation in postmitotic
neurons causes neuronal cell bodies to hypertrophy and subsequent
ventricular enlargement (Heumann et al., 2000; Hennekam, 2003).tal Biology, Hospital for Sick
College St., Toronto, Ontario,
l rights reserved.Moreover, components of the Ras signaling cascade, including SHP-2,
MEK, ERK2 and C/EBP have been shown to be play important roles in
cortical precursor cell neurogenesis (Gauthier et al., 2007; Ménard
et al., 2002; Paquin et al., 2005; Samuels et al., 2008, 2009). In contrast,
activation of the gp130-JAK-STAT pathway by cardiotrophin-1 has
been shown to be required for astrocyte formation (Bonni et al., 1997;
Barnabé-Heider et al., 2005).
Recent evidence suggests that germline mutations in Ras pathway
proteins are the cause of the neuro-cardio-facial-cutaneous (NCFC)
syndromes (Bentires-Alj et al., 2006). These syndromes include
Noonan syndrome, Costello syndrome (CS), neuroﬁbromatosis-1
(NF1), LEOPARD syndrome, and cardio-facio-cutaneous syndrome.
Individuals with these disorders present with a combination of facial
abnormalities and heart defects. Importantly, mental retardation and
cognitive dysfunction are also common. In this regard, we recently
asked whether aberrant development of neural precursors might
contribute to the cortical abnormalities seen in this family of
disorders, and focused upon Noonan syndrome, where the SHP2
protein tyrosine phosphatase is aberrantly activated (Gauthier et al.,
2007). These studies demonstrated that SHP2-mediated dysregula-
tion of the MEK-ERK and gp130-JAK-STAT pathways caused aberrant
genesis of neurons and glial cells in the embryonic cortex, and
provided support for the idea that neural precursor dysfunction might
441A. Paquin et al. / Developmental Biology 330 (2009) 440–451be an underlying cause of perturbed neural development and the
resultant cognitive deﬁcits in this family of disorders.
Costello syndrome is onemember of the NCFC family of syndromes
where all of the patients show mental retardation (Costello 1971,
1977). Moreover, imaging studies of CS patients show that close to 50%
show neuroanatomical perturbations including corpus collosum
agenesis, enlarged ventricles, frontal and cerebellar atrophy, cerebellar
malformations, hypodense white matter, and hydrocephalus (Delrue
et al., 2003;Hennekam, 2003; Gripp et al., 2002; Gripp, 2005; Zampino
et al., 2007). Recently, pointmutations inH-Ras have been identiﬁed as
responsible for causing this disorder (Aoki et al., 2005). In about 80% of
cases, themutation is situated at position 12 in the guanine nucleotide
binding site. These mutations result in decreased GTP hydrolysis,
causing increased and sustained Ras activity, and thus act as gain of
function mutations. These ﬁndings, together with previous work
suggesting that components of the Ras pathway regulate cortical
development, suggest that the cortical abnormalities seen in CS may
well be a consequence of perturbed cortical cell genesis. Further
support for this idea comes fromwork on theNF1 gene, which encodes
a tumor suppressor that, amongst several activities, is a negative
regulator of Ras (Hegedus et al, 2007). There is a high incidence of
cognitive dysfunction in NF1 patients (Hyman et al., 2005), and mice
where NF1 is genetically ablated in CNS precursors exhibit a variety
of deﬁcits in glial cells, including globally reactive astrogliosis and
increased proliferation of glial precursor cells (Zhu et al., 2005;
Hegedus et al., 2007). On the basis of these ﬁndings, we have
hypothesized that aberrant H-Ras activation causes cognitive
dysfunction by perturbing the proliferation and the differentiation
of neural precursor cells and their progeny.
Here, we provide evidence in support of this hypothesis,
demonstrating that expression of two Costello syndrome H-Ras alleles
in cortical precursors enhances cell proliferation and inhibits
neurogenesis in vivo. We also demonstrate that they cause premature
gliogenesis, which ultimately leads to an increase in astrocytes
postnatally. These ﬁndings suggest that aberrant H-Ras activation
disrupts normal cortical development and this may explain the
cortical abnormalities seen in CS.
Materials and methods
Culture of cortical precursor cells
Cortical precursor cells were cultured as previously described
(Barnabé-Heider and Miller, 2003; Paquin et al., 2005; Gauthier et al.,
2007). Brieﬂy, cortices were dissected from embryonic day 12 (E12) to
E13 CD1 mouse embryos in ice-cold HBSS (Invitrogen, Gaithersburg,
MD) and transferred to neurobasal medium (Invitrogen) containing
500 μm L-glutamine (Cambrex Biosciences, Hopkinton, MA), 2% B27
supplement (Invitrogen), and 1% penicillin-streptomycin (Invitrogen).
The medium was supplemented with 40 ng/ml FGF2 (Promega,
Madison, WI). The tissue was mechanically triturated with a plastic
pipette into single cells and cells were plated on two-well chamber
slides (Nunc, Naperville, IL). Chamber slides were previously coated
with 2% laminin and 1% poly-D-lysine (BD Biosciences, Bedford, MA)
and cell density was 250,000 cells/well.
Transfection and CNTF stimulation of cortical precursor cells
For transfections, 1 to 2 h after plating, 2 μg of DNA and 3 μl of
Fugene 6 (Roche,Welwyn Garden City, UK) mixed with 200 μl of Opti-
MEM (Invitrogen) were incubated at room temperature for 45 min
and then added to eachwell. The H-RasG12V and H-RasG12S plasmids
consist of point mutations at codon 12 (GGC) where glycine is
mutated to a valine (GTC) or a glycine (AGC) respectively. H-RasG12S
was generated by site-directed mutagenesis from the H-RasG12V
plasmid (Clontech, cat#631924). An empty vector was used as acontrol (pEF-GM), and a plasmid encoding EGFP under the CMV-
promoter (pEGFP) was used as a marker for cotransfected precursor
cells (Paquin et al., 2005; Gauthier et al., 2007). The day following
plating, 50 ng/ml ciliary neurotrophic factor (CNTF; Peprotech, Rocky
Hill, NJ) was added in some experiments (as speciﬁed), by changing
one half of the medium.
In utero electroporation
In utero electroporation was performed as previously described
(Paquin et al., 2005; Bartkowska et al., 2007; Gauthier et al., 2007).
Brieﬂy, E13/E14 CD1pregnantmicewere anesthesizedwith isoﬂurane,
and a midline incisionwas performed to access the embryos. A total of
4 μg of DNA was injected in the lateral ventricle of each embryo with
0.05% trypan blue as a tracer. We used a nuclear EGFP expression
plasmid driven from the EF1-promoter (pEF-GFP). This pEF-GFP was
coelectroporated with pEF-GM (empty vector), H-RasG12V, or H-
RasG12S. After injection, electroporation was performed using a
square electroporator CUY21 EDIT (TR Tech, Japan), delivering ﬁve
50 ms pulses of 40 V with 950ms intervals per embryo. Embryos were
then put back in utero and left to further develop for 3–8 days. For
analysis, brains were ﬁxed in 4% paraformaldehyde (PFA) (Electron
Microscopy Sciences, Hatﬁeld, PA) at 4 °C overnight, cryoprotected in
30% sucrose at 4 °C overnight, and embedded in OCT compound
(Sakura Finetek, Torrance, CA). The brains were kept at −80 °C until
cryosectioned (16 μm) and immunostained.
Immunocytochemistry
Immunocytochemistry of cultured cells and tissue sections was
performed as described (Paquin et al., 2005; Bartkowska et al., 2007;
Gauthier et al., 2007). For immunocytochemistry of cultured cells,
cells were washed with HEPES-buffered saline (HBS) and ﬁxed with
4% PFA for 15 min, permeabilized with 0.2% NP-40 (USB Corporation,
Cleaveland, OH) in HBS, and blockedwith buffer containing 6% normal
goat serum (NGS) (Jackson ImmunoResearch, West Grove, PA) and
0.5% bovine serum albumin (BSA) (Jackson ImmunoResearch) for 1–
2 h at room temperature. Cells were then incubated with primary
antibodies in HBS containing 3% NGS and 0.25% BSA at 4 °C overnight.
After washing with HBS, cells were incubated with secondary
antibodies prepared in HBS containing 3% NGS and 0.25% BSA at
room temperature for 1 h. Samples were then washed with HBS,
counterstained with Hoechst 33258 (1:1000; Sigma, St-Louis, MO) for
2 min, and mounted with GelTol (Fisher Scientiﬁc, Houston, TX). For
immunocytochemistry of tissue sections, sections were dried at 37 °C
for 15 min, washed in phosphate buffer solution (PBS) (Hyclone,
Logan, UT), and postﬁxed with 4% PFA for 10–15 min. They were then
blocked and permeabilized with 10% BSA and 0.3% Triton X-100 (EMD
Chemicals Inc., Gibbstown, NJ) for 1 h. TheM.O.M. blocking kit (Vector
Laboratories, Burlingame, CA) was then used according to the
manufacturer's protocol. Sections were incubated with primary
antibodies at 4 °C overnight, washed with PBS, and incubated with
secondary antibodies at room temperature for 1 h. They were then
counterstained with Hoechst 33258 for 2 min and mounted with
GelTol. The primary antibodies used were mouse anti-GFP (1:1000;
Invitrogen), rabbit anti-GFP (1:500; Chemicon, Temecula, CA), mouse
anti-H-Ras (1:400; Calbiochem), rabbit anti-phosphoErk (1:500, Cell
Signaling Technology), mouse anti-Ki67 (1:200; BD Biosciences),
mouse anti-HuD (1:200; Invitrogen), mouse anti-βIII-tubulin (1:800;
Covance, Princeton, NJ), rabbit anti-GFAP (1:1000, Accurate Chemical
and Scientiﬁc Corp., Westbury, NY), rabbit anti-cleaved caspase-3
(1:500; Cell Signaling Technology), and goat anti-doublecortin
(1:100; Santa Cruz). The secondary antibodies used for immuno-
cytochemistry were indocarbocyanine (Cy3)-conjugated goat anti-
mouse and anti-rabbit IgG (1:400; Jackson ImmunoResearch), (Cy3)-
conjugated donkey anti-goat IgG (1:1000; Jackson ImmunoResearch),
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ImmunoResearch), dichlorotriazinyl amino ﬂuorescein-conjugated
streptavidin (1:1000; Jackson ImmunoResearch), (Cy3)-conjugatedstreptavidin (1: 1000; Jackson ImmunoResearch), Alexa Fluor 350
goat anti-mouse and anti-rabbit (1:500; Moleclar Probes, Eugene,
OR), and Alexa Fluor 647 goat anti-mouse (1:1000; Molecular Probes).
Fig.1. ActivatedH-RasG12VandH-RasG12S increase proliferation andperturbdifferentiation of cultured cortical precursor cells. (A) Immunocytochemical analysis for EGFP (green) and
activated, phosphorylated Erk (red) in cortical precursor cells cotransfected with plasmids encoding EGFP and LacZ, or EGFP and H-RasG12V. Cells were cultured for 5 days
posttransfection. Cultureswere counterstainedwithHoechst 33258 (blue) to showall of the nuclei in theﬁeld. Arrows denote double-labeled cells. Scale bar=20 μm. (B)Quantiﬁcation
of transfected phospho-Erk-positive cells as shown inpanel (A) in 4 independent experiments. Error bars denote s.e.m. ⁎⁎⁎pb0.005. (C, E, G) Fluorescence photomicrographs of cultured
cortical precursors cotransfectedwithplasmids encoding EGFPand an empty vector (control), EGFPandH-RasG12V, or EGFPandH-RasG12S, as indicated. Cultureswere analyzed after 3
DIV (C, E) or 5 DIV (G) for EGFP (green) and Ki67 (C), βIII-tubulin (E), or GFAP (G) (all in red). Cells were counterstained with Hoechst 33258 (blue) to show nuclei. Arrows denote
double-labeled cells, while arrowheads indicate transfected cells negative for themarker. Scale bar: 50 μm. (D, F, H) Quantiﬁcation of the percentage of EGFP-positive cells also positive
for Ki67 (D),βIII-tubulin (F), or GFAP (H) in experiments similar to those shown inpanels (C), (E), or (G), respectively. In panels (D) and (H), the graphs represent combined data from3
independent experiments, while in panel (F), individual representative experiments (expt.) are shown. Error bars denote s.e.m. ⁎⁎⁎pb0.001, relative to control-transfected cultures.
Fig. 2. CS H-Ras mutants increase cortical precursor cell proliferation in vivo. Precursor cells of the embryonic cortex were transfected by in utero electroporation at E13/14 with
plasmids encoding nuclear EGFP and an empty vector (control), EGFP and H-RasG12V, or EGFP and H-RasG12S, and then analyzed 3 days later at E16/17. (A) High magniﬁcation
confocal image of cells in the VZ/SVZ that were electroporated with EGFP and H-RasG12V, and immunostained for EGFP (green) and Ki67 (red; colocalization is yellow, and is
denoted by arrows; arrowheads denote singly-labeled cells). Scale bar, 20 μm. (B, C) Quantiﬁcation of the number of transfected, EGFP and Ki67-positive cells as a percentage of total
transfected cells in the entire cortex. (D, G) Confocal micrographs of coronal sections through the ventricular zone/subventricular zone (VZ/SVZ; D) or cortical plate (CP; G) of
transfected cortices that were immunostained for EGFP (green) and the proliferation marker Ki67 (red). The red boxes in the lowmagniﬁcation images on the left indicate the areas
that are shown in the higher magniﬁcation images. The right panels show the merged images. Arrows indicate transfected cells that are positive for both EGFP and Ki67, while
arrowheads denote cells that are positive for EGFP or Ki67 only. In (D), the hatched lines outline the VZ/SVZ, while in (G) the hatched lines outline the cortical plate. V, ventricle; M,
meninges. Scale bar, 100 μm. (E, F, H, I) Quantiﬁcation of the number of EGFP-positive transfected cells in the VZ/SVZ (E, F) or in the cortical plate (H, I) that was also positive for Ki67,
as shown in panels (D) and (G). Numbers in panels (B), (C), (E), (F), (H), and (I) were obtained from analysis of 3–5 littermate pairs, four to ﬁve sections per embryo for each
comparison between control and experimental groups. In total, an average of 110–192 cells/section was counted in each of 20–33sections, for a total of 2641–6326 cells per
experimental group. Error bars indicate s.e.m. ⁎⁎pb0.01, ⁎⁎⁎b0.001 relative to control-transfected sections.
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Fig. 3. CS H-Ras mutants decrease neurogenesis in vivo. Precursor cells of the embryonic cortex were transfected by in utero electroporation at E13/14 with plasmids encoding
nuclear EGFP and an empty vector (control), H-RasG12V, or H-RasG12S, and then analyzed 3 days later at E16/17 (A–H) or at postnatal day 3 (I). (A) Confocal micrographs of
electroporated cortical sections that were immunostained for EGFP (green) and the neuronal marker HuD (red). The red boxed area in the low magniﬁcation image on the left
indicates the area that is shown in the higher magniﬁcation images. The right panels show the merged images. IZ, intermediate zone; CP, cortical plate; V, ventricle; M, meninges.
Scale bar, 100 μm. (B) Higher magniﬁcation confocal images of a section similar to that shown in (A). Arrows indicate transfected cells that are positive for both EGFP and HuD. Scale
bar, 50 μm. (C, E) Quantiﬁcation of control and H-RasG12V (C) or H-RasG12S (E) transfected cells that were located within the cortical plate as a percentage of total EGFP transfected
cells. (D, F, G) Quantiﬁcation of the number of transfected, EGFP-positive, HuD-positive cells as a percentage of total transfected cells in the entire cortex (D,F), or speciﬁcally in the
cortical plate (G). (H) Confocal micrographs of electroporated cortical sections that were immunostained for EGFP (green) and the apoptotic marker cleaved caspase-3 (CC3, red).
The right panels show themerged images and arrowheads denote cells that were positive for CC3. (I) Quantiﬁcation of the number of transfected, EGFP-positive, HuD-positive cells as
a percentage of total transfected cells in the entire cortex at P3. Numbers in (C–G, I) were obtained from analysis of 3–5 littermate pairs, four to ﬁve sections per embryo for each
comparison between control and experimental groups. For (C, E), an average of 38–138 cells/section was counted in each of 22–38 sections, for a total of 1519–5241 cells per
experimental group. For (D,F), an average of 76–180 cells/section was counted in each of 16–48 sections for a total of 1215–7123 cells per experimental group. For (G), an average of
16–23 cells/sectionwas counted in each of 16–17 sections for a total of 276–394 cells per experimental group. For (I), an average of 46–53 cells/sectionwas counted in each of 16–24
sections for a total of 749–1329 cells per experimental group. Error bars indicate s.e.m. ⁎⁎pb0.01, ⁎⁎⁎pb0.001 relative to control-transfected sections.
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For quantiﬁcation of immunocytochemistry on cultured cells,
approximately 300 cells per condition per experiment were counted
and analyzed in at least 15 randomly selected ﬁelds spanning the
culture well. Digital image acquisition was performed with Northern
Eclipse software (Empix, Mississauga, Ontario, Canada) using a Sony
(Tokyo, Japan) XC-75CE CCD video camera. In all cases at least 3
independent experiments were performed and these data were
pooled unless otherwise indicated. For quantiﬁcation of immuno-
cytochemistry on tissue sections, brains were chosen with a similar
anatomical distribution and level of EGFP expression. Images of the
electroporated dorsal telencephalon were taken and covered the
ventricular zone, subventricular zone, and cortical plate of each
coronal section. A total of four to ﬁve sections were analyzed per
animal and 3–5 littermate pairs were analyzed per condition.
Images represented a mean of four scans taken with a 40× objective
and were analyzed using a Zeiss Pascal confocal microscope and the
manufacturer's software (Oberkochen, Germany). The actual num-
ber of cells counted is indicated in the ﬁgure legends. Error bars
indicate s.e.m., and the statistics were performed using the
Student's t test.
Results
Costello syndrome H-Ras mutants promote proliferation and
astrogenesis in cultured cortical precursors
The hyperactivated H-Ras mutations found in Costello syndrome
cause cortical abnormalities (Gripp, 2005; Zampino et al., 2007). To
ask if they might do this by perturbing neural precursor development,
we examined cortical precursor cells that were isolated from the E12.5
to E13.5 mouse cortex and plated in the presence of FGF2, which is
essential for cortical precursor proliferation (Ghosh and Greenberg,
1995; Raballo et al., 2000). We have shown previously that, upon
plating, these cells are dividing, nestin-positive precursors (Slack
et al., 1998; Ménard et al., 2002). Over the next 3–5 days in culture,
many of these precursors exit the cell cycle to become neurons, while
after 5 days the same pool of precursors starts to generate astrocytes
(Barnabé-Heider and Miller, 2003; Paquin et al., 2005; Gauthier et al.,
2007), a temporally-regulated sequence of events that also occurs in
vivo (Qian et al., 2000). We transfected these precursors with
plasmids encoding one of two Costello syndrome H-Ras mutants
that together comprise approximately 80% of patients with this
syndrome; both of these mutations affect amino acid 12, and involve
mutations from glycine to valine (H-RasG12V) or serine (H-RasG12S).
To follow transfected precursors, we cotransfected them upon plating
with plasmids encoding EGFP and one of the two CS mutants. In
agreement with our previous work (Paquin et al., 2005; Bartkowska
et al., 2007), more than 80% of the cells that expressed EGFP also
expressed H-Ras, indicating the reliability of the cotransfection
approach.
We ﬁrst conﬁrmed that the CS Ras mutants stimulated the activity
of Erk1/2, a downsteam target of Ras, in cortical precursors as they do
in other cell types (Seeburg et al., 1984; Mazzoni et al., 1999). Plasmids
encoding H-RasG12V or LacZ were cotransfected with the EGFP-
expression plasmid into freshly-plated cortical precursor cells.
Immunocytochemical analysis 5 days later for EGFP and the
phosphorylated, activated Erk1/2 revealed that whereas fewer than
20% of the control LacZ-transfected cells expressed detectable levels of
phospho-Erk, approximately 60% of the H-RasG12V-transfected cells
were phospho-Erk-positive (Figs. 1A, B). Thus, CS H-Ras mutants are
active in cortical precursors, as they are in other cells.
To determine whether CS H-Ras mutants promoted aberrant
proliferation of precursors, similarly-transfected cells were analyzed
after 3 days in culture by double-label immunocytochemistry for EGFPand Ki67, a marker for proliferating cells (Fig. 1C). The proliferation of
cells transfected with H-RasG12V or H-RasG12S was increased 1.5 to
2-fold relative to control plasmid-transfected cells (Fig. 1D).
To ask whether CS H-Ras mutants also perturbed differentiation,
we performed the same cotransfections and immunostained for the
neuron-speciﬁc protein βIII-tubulin (Fig. 1E), or the astrocyte protein
GFAP (Fig. 1G). To ask about neurogenesis, we performed this
analysis at 3 or 5 days posttransfection. Quantiﬁcation showed that
both H-RasG12V and H-RasG12S decreased the number of neurons
that were generated in these cultures (Fig. 1F). To ask about
astrogenesis, cultures were treated with ciliary neurotrophic factor
(CNTF) upon transfection, and then were analyzed 5 days later. CNTF
treatment of cortical precursor cell cultures induces astrocyte
formation (Bonni et al., 1997; Barnabé-Heider et al., 2005), and
thus allows us to study astrogenesis in vitro in a timely manner.
Double-label immunocytochemistry for EGFP and GFAP revealed that
both H-Ras mutants increased the number of astrocytes that were
present relative to controls by approximately two-fold (Fig. 1H).
Thus, sustained activation of H-Ras in cultured cortical precursors
increases both cell proliferation and astrogenesis, while coincidently
decreasing neurogenesis.
Sustained H-Ras activation promotes proliferation of cortical precursors
in vivo
To ask whether the CS H-Ras mutants affected cortical precursors
in the embryo as they did in culture, we performed in utero
electroporation. We have previously shown that cortical precursors
that are transfected at E13.5 in vivo proliferate within the ventricular
and subventricular zones (VZ/SVZ) and that over time, these
transfected precursors generate ﬁrst neurons, and then glial cells, as
do nontransfected cortical precursors (Paquin et al., 2005; Bartkowska
et al., 2007; Gauthier et al., 2007). Plasmids encoding a nuclear EGFP
and either the empty vector, or one of the two CS H-Rasmutants, were
coelectroporated after injection into the E13–14 embryo lateral
ventricles and these embryos were examined 3 days later. Coronal
sections through the cortex of these electroporated embryos were
double-labeled for EGFP and Ki67 (Fig. 2A) and confocal microscopy
was used to determine the percentage of EGFP-positive cells that
expressed Ki67 (Figs. 2B, C). We also determined the percentage of
proliferating, transfected cells in the VZ/SVZ, which at this timepoint
contains precursor cells and newly-born neurons, and the cortical
plate, which is comprised of newly-born neurons postmigration. This
analysis revealed that, at this timepoint, 7–11% of total control cells
were Ki67-positive (Figs. 2B, C), as we have previously published
(Paquin et al., 2005; Bartkowska et al., 2007; Gauthier et al. 2007).
Virtually all of these proliferating cells were in the VZ/SVZ, consistent
with a precursor cell phenotype, with none, or very few transfected,
proliferating cells in the cortical plate, also consistent with the fact
that newly-born neurons exit the cell cycle within the VZ/SVZ before
they migrate to the cortical plate. In contrast, approximately 20–25%
of the H-RasG12V and H-RasG12S transfected cells were Ki67-positive
(Figs. 2B, C), a 2-to-3-fold increase relative to controls. Moreover,
while much of this increase occurred in precursors in the VZ/SVZ
(Figs. 2D–F), many EGFP-positive, Ki67-positive cells were also
observed in the cortical plate (Figs. 2G–I), something that was rarely
observed in controls. Thus, the increased H-Ras activity that occurs
with CS mutations promotes aberrant proliferation of cortical
precursor cells and potentially even newly-born neurons in vivo.
Costello syndrome H-Ras mutants decrease neurogenesis in vivo
To ask whether H-Ras sustained activation also affected cell genesis
in the embryonic cortex, as it did in culture, we performed similar in
utero electroporations with plasmids encoding nuclear EGFP and the
empty vector, H-RasG12V, or H-RasG12S, and analyzed these embryos
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cortex during the neurogenic period, 3 days postelectroporation,
performing double-label immunocytochemistry for EGFP to identifytransfected cells, and the neuron-speciﬁc protein HuD, to identify the
cortical plate and newly-born neurons (Figs. 3A, B). Analysis of the
location of the EGFP-positive cells within the embryonic cortex
Fig. 5. CS H-Ras mutants cause premature astrogenesis embryonically. Precursor cells of the embryonic cortex were transfected by in utero electroporation at E13/14 with plasmids
encoding nuclear EGFP and an empty vector (control), H-RasG12V, or H-RasG12S, and then analyzed 3 (A–C), or 4.5 (D) days postelectroporation. (A, B, D) Confocal micrographs of
cortical sections electroporated with empty vector (control, A, D), H-RasG12S (A, B) or H-RasG12V (D) and then immunostained for EGFP (green) and GFAP (red) 3 days (A,B), or
4.5 days (D) postelectroporation. In (A), the right panels show the merged images, and the hatched lines outline the VZ/SVZ. In panel (B) the images are higher in magniﬁcation to
show double-labeled cells with more resolution (arrows). In panel (D), the left panels show lower magniﬁcation images, and the hatched lines outline the tissue margins. The right
panels show higher magniﬁcation images of the region adjacent to the ventricles (V; denoted by hatched lines). In all cases, arrows denote double-labeled cells. Scale bar, 50 μm (A);
20 μm (B); 100 μm (D, left panels) and 50 μm (D, right panels). V, ventricle; M, meninges. (C) Quantiﬁcation of the number of transfected cells positive for GFAP as a percentage
of total transfected cells at 3 days postelectroporation. Numbers are pooled from at least 6 different experiments, each involving the analysis of 3–5 littermate pairs, four to ﬁve
sections per embryo for each comparison between control and experimental groups. For (C), an average of 86–151 cells/section was counted in each of 37–56 sections, for a total of
4303–5600 cells per experimental group. Error bars indicate s.e.m. ⁎⁎⁎b0.001 relative to control-transfected sections.
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were present within the cortical plate, presumably because they had
become neurons and migrated there, only about half as many of the
cells transfected with the CS H-Ras mutants were located in this
region (Figs. 3C, E). Confocal analysis of cells coexpressing both
EGFP and HuD (Fig. 3B) revealed a similar decrease in the number
of neurons generated from transfected precursors; transfection with
the CS H-Ras mutants decreased the percentage of EGFP-positive,
HuD-positive neurons by two-or-more-fold (Figs. 3D, F). Moreover,
of those transfected cells that had migrated to the cortical plate,Fig. 4. CS H-Ras mutants promote astrocyte proliferation in vivo. Precursor cells of the em
encoding nuclear EGFP and an empty vector (control), H-RasG12V, or H-RasG12S, and then
electroporated with H-RasG12S and triple-labeled for EGFP (green), the early neuronal mark
the merged images. Arrows indicate cells double-labeled for EGFP and Ki67 (A) or EGFP and
25 μm (A), 10 μm (B). (C) Confocal micrographs of a cortical section electroporated with H-R
(blue). The right panels show the merged image. The bottom panels show higher magniﬁcat
The hatched lines in the top panels outline the VZ/SVZ. V; ventricle, CM; cortical mantle. Scale
images of a cortical section electroporatedwith H-RasG12S, and triple-labeled for EGFP (green
cell in all panels. The top right panel shows the merged image for EGFP and Ki67, and the bot
the number of transfected cells positive for Ki67 (E), or GFAP (F) as a percentage of total tran
both Ki67 and GFAP, as a percentage of total GFAP-positive transfected cells in the entire corte
and GFAP, as a percentage of total transfected, Ki67-positive cells in the cortical plate (CP). (I)
VZ/SVZ versus cortical plate as a percentage of the total transfected, Ki67-positive, GFAP-pos
ﬁve sections per embryo for each comparison between control and experimental groups. In to
of 3674–5239 cells per experimental group. Error bars indicate s.e.m. ⁎b0.05; ⁎⁎b0.01; ⁎⁎⁎bfewer CS H-Ras-transfected cells expressed detectable levels of HuD
(Fig. 3G).
These data support the conclusion that CS H-Ras mutants
decrease neurogenesis. To verify this conclusion, we performed a
number of additional experiments. First, we asked whether the
decrease in neuronal numbers might be due to increased apoptosis
of newly-born neurons that expressed activated H-Ras. To do this, we
performed immunocytochemistry for cleaved caspase-3 on cortices
that were electroporated with plasmids encoding nuclear EGFP and
the empty vector or H-RasG12S for 3 days (Fig. 3H). This analysisbryonic cortex were transfected by in utero electroporation at E13/14 with plasmids
analyzed 4.5 days later at E17.5/18.5. (A, B) Confocal micrographs of cortical sections
er βIII-tubulin or doublecortin (DCX) (both red) and Ki67 (blue). The right panel shows
doublecortin (B). Arrowheads in (B) indicate a cell that expresses EGFP only. Scale bar,
asG12V and triple-labeled for EGFP (green), Ki67 (red) and the astrocyte marker GFAP
ion images of the section shown in the top panels. Arrows indicate a triple-labeled cell.
bar, 50 μm(upper panels) and 25 μm (bottom panels). (D) Highmagniﬁcation confocal
), Ki67 (upper panels, red), and GFAP (bottom panels, red). The arrow denotes the same
tom right the merged image for EGFP and GFAP. Scale bar, 10 μm. (E, F) Quantiﬁcation of
sfected cells. (G) Quantiﬁcation of the number of transfected cells that were positive for
x. (H) Quantiﬁcation of the number of transfected cells that were positive for both Ki67
Quantiﬁcation of the number of transfected cells positive for both Ki67 and GFAP in the
itive cells. Numbers in (E–I) were obtained from analysis of 3–5 littermate pairs, four to
tal, an average of 105–276 cells/sectionwas counted in each of 19–35 sections, for a total
0.001 relative to control-transfected sections.
Fig. 6. CS H-Ras mutants increase astrocyte number postnatally. Precursor cells of the embryonic cortex were transfected by in utero electroporation at E13/14 with plasmids
encoding nuclear EGFP and an empty vector (control), H-RasG12V, or H-RasG12S, and then analyzed at postnatal day 3 (P3). (A, B) Confocal micrographs of cortical sections
electroporated with empty vector (control) or H-RasG12S and then immunostained for EGFP (green) and GFAP (red). The cortical plate (CP) is shown in (A), and the VZ/SVZ in (B) as
denoted by the red boxes in the tissue images to the right. The hatched lines denote the boundaries of the cortical plate (A) or the ventricular margin (B). M, meninges. Scale bars,
50 μm. (C–E) Quantiﬁcation of the number of transfected cells positive for GFAP as a percentage of total transfected cells in the entire cortex (C), in the VZ/SVZ (D), or in the cortical
plate (E). Numbers are pooled from at least 3 different experiments, each involving the analysis of 3–5 littermate pairs, four to ﬁve sections per embryo for each comparison between
control and experimental groups. In total, an average of 28–55 cells/section was counted in each of 17–27 sections, for a total of 469–1258 cells per experimental group. Error bars
indicate s.e.m. ⁎⁎b0.01; ⁎⁎⁎b0.001 relative to control-transfected sections.
448 A. Paquin et al. / Developmental Biology 330 (2009) 440–451demonstrated that only 1–3 cells per section were positive for
cleaved caspase-3, and that this was similar in both the control and
H-Ras-electroporated cortices. Second, we asked whether the
decrease in neuronal numbers was persistent by performing
electroporations at E13/14, and then analyzing the electroporated
cortices at postnatal day 3. Quantiﬁcation revealed that, even at this
later timepoint, expression of the CS H-Ras mutants caused adecrease in the total number of EGFP-positive, HuD-positive neurons
(Fig. 3I). Finally, to ask whether this decrease reﬂected a deﬁcit in
neuronal migration, we looked speciﬁcally at the number of HuD-
positive neurons present in the VZ/SVZ. This analysis showed that
only 0.2%–0.3% of HuD-positive cells were in the VZ/SVZ and that
this number was similar in cortices electroporated with the empty
vector versus CS H-Ras mutants (PN0.05). Together, these data argue
449A. Paquin et al. / Developmental Biology 330 (2009) 440–451that CS H-Ras mutants directly decreased neurogenesis from cortical
precursors in vivo.
Costello syndrome H-Ras mutants enhance proliferation of
newly-generated astrocytes in vivo
These data indicate that CS H-Ras mutants caused increased
precursor proliferation, decreased neuronal genesis, and the aberrant
appearance of proliferating cells within the cortical plate. To ask
whether these aberrantly-proliferating cells within the VZ/SVZ and
cortical plate were or would become neurons or astrocytes, we
performed in utero electroporations, and analyzed the electroporated
cells 4.5 days later, immediately prior to birth. To ask if these
proliferating cells were newly-born neurons that had not exited the
cell cycle, we triple-labeled coronal sections through electroporated
brains for EGFP, to monitor transfected cells, Ki67 to monitor
proliferating cells, and one of two early neuronal markers, βIII-tubulin
(Fig. 4A) or doublecortin (Fig. 4B). Confocal microscopy analysis
revealed that only rare cells coexpressed βIII-tubulin or doublecortin
and Ki67, regardless of the cortical region, and regardless of whether
they were transfected with CS H-Ras mutants. We therefore
performed similar analyses, triple-labeling for EGFP, Ki67, and GFAP
to ask whether these proliferating cells were astrocytes (Figs. 4C, D).
Confocal analysis demonstrated that, as seen at 3 days postelectro-
poration, at 4.5 days postelectroporation, transfection with CS H-Ras
mutants caused an increase in the percentage of proliferating cells of
approximately three-fold (Fig. 4E). Moreover, transfection with H-
RasG12V caused an approximately four to ﬁve-fold increase in the
percentage of astrocytes, while transfection with H-RasG12S caused a
more modest, but still signiﬁcant increase in astrogenesis (Fig. 4F).
Interestingly, of those CS H-Ras mutants that had become astrocytes,
many of them were still proliferating, something that was only
occasionally seen in controls at this age (Fig. 4G). In addition, many
of the Ki67-positive cells that were aberrantly observed in the
cortical plate following CS H-Ras transfection also expressed GFAP
(Fig. 4H), indicating that they were proliferating astrocytes. More
speciﬁcally, in empty vector-electroporated cortices, all of the
transfected proliferating astrocytes (Ki67-positive, GFAP-positive,
GFP-positive cells) were localized to the VZ/SVZ, while in cortices
electroporated with CS H-Ras mutants, approximately 60–80% were
in the VZ/SVZ, with as many as 20–30% localized to the cortical plate
(Fig. 4I). The identity of the remaining proliferating cells within the
cortical plate that did not express either neuronal or astrocytic
markers is still unclear, since they did not express the oligodendro-
cyte marker O4, and only very few expressed the cortical radial
precursor marker Pax6 (data not shown). Thus, sustained H-Ras
activation promotes the genesis and/or proliferation of astrocytes,
and some of these proliferating astrocytes are aberrantly localized
within the cortical plate.
Sustained H-Ras activation promotes premature gliogenesis in the
embryonic cortex
During murine cortical development, gliogenesis starts at E18,
peaks after birth, and continues postnatally. Ourdatawith the CSH-Ras
mutants indicate that they increase the number of astrocytes
generated in the embryonic cortex either by promoting the genesis
of astrocytes and/or by increasing proliferation of previously-
generated astrocytes. To distinguish these two possibilities, we asked
whether gliogenesis occurred prematurely in brains electroporated
with either of the CS H-Ras mutants. Immunocytochemical analysis of
brains electroporated at E13/14 and examined 3 days later revealed
that, as predicted, no EGFP-positive, GFAP-positive cells were ever seen
in control brains at this timepoint. In contrast, a subpopulation of H-
RasG12VandH-RasG12S-transfected cells expressedGFAP (Figs. 5A–C),
indicating that Ras activation promoted premature genesis and/ordifferentiation of astrocytes. However, none of these EGFP-positive,
GFAP-positive cells localized to the cortical plate, indicating that
the aberrantly-proliferating cortical plate cells seen at this timepoint
were likely precursor cells. Experiments were also performed 4.5 days
after electroporation and revealed that as astrogenesis is starting in
controls, brains transfected with H-RasG12V, or H-RasG12S, showed
many GFAP-positive cells (Fig. 5D), consistent with the data 3 days
postelectroporation. To determine whether H-Ras activity also
ultimately increased the number of astrocytes, we examined
electroporated brains at postnatal day 3 (P3) (Figs. 6A, B). Confocal
microscopy showed that in the control brains, 25 to 30% of the total
transfected cells were GFAP-positive, while in the H-RasG12V and
H-RasG12S, approximately 40–55% of the total transfected cells were
GFAP-positive (Fig. 6C). In addition, quantiﬁcation demonstrated that
astrocytes increased from approximately 20% in the controls to
approximately 60 to 80% in the H-Ras mutants for the VZ/SVZ, and
from approximately 18% in the controls to 40 to 50% in the H-Ras
mutants for the cortical plate (Figs. 6D, E). Thus, not only do CS H-Ras
mutants cause premature astrogenesis, but they also robustly
increase the number of astrocytes present postnatally.
Discussion
The data presented here support three major conclusions. First,
sustained activation of H-Ras promotes proliferation of cortical
precursor cells in vivo. Second, this aberrant activation decreases the
differentiation of cortical precursors into neurons. Finally, constitutive
activation of H-Ras leads to premature formation of astrocytes, and
ultimately increases the number of astrocytes postnatally. Thus, by
perturbing the proliferation and differentiation of cortical precursors,
sustained H-Ras activation disrupts the balance between the numbers
of neurons and astrocytes, which can result in cortical dysgenesis and
thus likely contribute to the cognitive impairments seen in Costello
syndrome (CS).
CS patients all share multiple phenotypes. They have common
facial traits, skin papillomata, short stature, and growth retardation.
They present with heart defects, most often hypertrophic cardiomyo-
pathies, and neurological conditions including ventricular dilatation
that requires a ventriculo-peritonial shunt, hydrocephaly, Chiari 1
malformation, and seizures (Delrue et al., 2003; Hennekam, 2003;
Gripp et al., 2002, Gripp, 2005; Zampino et al., 2007). In the majority
of CS cases, mutations are found at codon 12 in H-Ras. The most
common of these involve H-RasG12S, which accounts for approxi-
mately 80% of cases (Aoki et al., 2005), with H-RasG12V accounting for
a further 5% of cases. This latter mutation is highly tumorigenic
(Fasano et al., 1984; Seeburg et al., 1984), and its prevalence in CS is
likely low as a consequence. In this regard, cancers, including
neuroblastomas, rhabdomyosarcomas and bladder carcinomas, are
more common in patients with CS than in any of the other NCFC
syndromes likely because of the high relative tumorigenicity of H-Ras
mutations in general.
Data presented here demonstrate that CS H-Ras mutants perturb
neural precursor development in two ways; they induce these
precursors to generate more astrocytes and fewer neurons, and they
cause hyperproliferation of both precursors and newly-generated
astrocytes. How does H-Ras activation promote astrogenesis and
decrease neurogenesis? We propose that they do so by maintaining
cells in a proliferative state, preventing precursors fromdifferentiating
into neurons at the appropriate timepoint, and thereby ultimately
enhancing astrogenesis. In the CNS, neuronal differentiation is tightly
coupled to cell cycle exit. In this regard, pRb plays a key role in linking
cell cycle exit and neuronal gene expression as cortical precursors
become postmitotic neurons (Toma et al., 2000), and Ras is known to
regulate pRb to promote S-phase entry (Leone et al., 1997; Peeper
et al., 1997). Thus, by directly regulating pRb and potentially other cell
cycle regulators, activated Ras could prevent cell cycle exit and inhibit
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precursors in the cortical plate region in this study, something that
was also seenwhen the cell cycle inhibitors p19Ink4d and p27Kip1 were
genetically ablated (Zindy et al., 1999). What happens then to these
precursors that would normally make neurons, but have been
inhibited from doing so by H-Ras activation? Our data indicate that
they persist as cycling precursors throughout the neurogenic period.
We suggest that they then ﬁnd themselves in a neural environment
that favors astrogenesis (Miller and Gauthier, 2007; Barnabé-Heider
et al., 2005), and since there is no obligate link between cell cycle exit
and adopting an astrocyte phenotype, they become astrocytes.
The second major phenotype we have documented here is
hyperproliferation of cortical precursors and the astrocytes that they
generate. These ﬁndings are relevant not only for the perturbed neural
morphogenesis seen in CS, but also for the increased tumorigenesis
seen in this syndrome. These ﬁndings may also have relevance for
other NCFC syndromes, and in particular for neuroﬁbromatosis-1
(NF1). NF1 is a tumor suppressor that functions as a negative
regulator of Ras. Approximately 15–20% of children with NF1 develop
low-grade glial cell neoplasms (Listernick et al., 1994, 1999) and in
mice, inactivation of the NF1 gene leads to increased proliferation of
glial precursors and increased astrogenesis that ultimately results in
formation of optic gliomas (Bajenaru et al., 2001, 2002, 2003; Zhu
et al., 2005). These phenotypes are at least partially due to inactivation
of NF1 in neural precursors since genetic ablation of NF1 in cultured
neural stem cells or in BLBP-positive radial precursors in vivo
enhanced gliogenesis (Dasgupta and Gutmann, 2005; Hegedus et al.,
2007). Thus, activation of Ras either by inactivation of NF1 or by direct
mutation, is sufﬁcient to cause enhanced proliferation of glial
precursors and astrocytes. However, while inactivation of NF1 had
some effects on neuronal maturation (Hegedus et al., 2007), it did not
decrease neurogenesis, arguing that while related, these two
perturbations are distinct, consistent with the differences in cognitive
impairments seen in these two disorders.
These ﬁndings provide a cellular mechanism to explain the severe
cognitive deﬁcits seen in CS patients. During development of the
mammalian nervous system, cell genesis is a timed event, with
neuronal genesis occurring ﬁrst, followed by glial genesis. These
neurogenic and gliogenic periods are growth factor mediated and
temporally distinct; within the murine cortex, for example, neuro-
genesis occurs from approximately E12 to E17 while astrocyte
formation is largely postnatal. This process is biologically-logical:
neuronal circuitry is established ﬁrst and then the numbers of glial
cells are matched to that circuitry. Perturbation of these highly
conserved events, in either timing or magnitude, could result in
signiﬁcant cortical abnormalities. In this regard, our ﬁnding that
activated H-Ras actively promotes gliogenesis at the expense of
neurogenesis is highly relevant. Previously published data from our
group showed that sustained activation of SHP-2, as seen in Noonan
syndrome, caused increased neurogenesis and decreased gliogenesis
in vivo (Gauthier et al., 2007). How then can these different
mutations, which cause opposite effects on neural cell genesis, still
cause similar impairment of cognitive function? We propose two
potential explanations. First, it is not speciﬁcally the change in the
number of neurons or astrocytes that causes mental dysfunction, but
rather the overall balance between the two. Clearly the number of
neurons would be critical to the establishment of appropriate neural
circuitry, but emerging evidence indicates that the number of
astrocytes is also important. When astrocyte numbers are decreased,
this can lead to neuronal degeneration and dysfunction (Wagner et al.,
2006), and astrocytes are now known to play a role in communication
at the level of the synapse (Araque et al., 1999; Bezzi et al., 2004; Perra
and Araque, 2007). Second, the timing of neurogenesis versus
astrogenesis is key to the proper generation of neural architecture.
For example, when neurons are born is a key determinant of their
ultimate locationwithin the cortex; when neurogenesis is acutely andtransiently interrupted, the neurons that are inappropriately born
later now localize to more superﬁcial cortical layers (Mizutani and
Saito, 2005; Paquin et al., 2005). Thus, perturbations at the level of the
timing or extent of differentiation, as caused by CS H-Ras mutations,
can affect cortical development, the efﬁciency and the functionality of
the circuitry, and ultimately lead to mental retardation.
In summary, data presented here, together with previous work
(Gauthier et al., 2007; Samuels et al., 2008), support the concept that
the perturbations of the Ras-MAPK pathway that are seen in the NCFC
disorders dysregulate neural precursor development, thereby causing
the deﬁcits in cognitive function that are seen in this family of genetic
syndromes. Whether similar perturbations in neural precursor cell
development play a role in other genetic syndromes that alter
cognitive function is a key question for the future.
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